Atlas Trials

An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)

Clinical trial NCT05146882 · WITHDRAWN

Trial details

NCT number
NCT05146882
Sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Alpha 1-Antitrypsin Deficiency
Start date
2021-12-01
Primary completion
2022-05-23
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.